Objective-Endothelial cell activation is an important mediator of monocyte recruitment to sites of vascular inflammation.
I nflammation, notably macrophage infiltration, is an important determinant in the pathogenesis of atherosclerosis. 1, 2 Macrophages are involved in all stages of atherosclerotic lesion development and may trigger clinical events such as myocardial infarction or stroke by promoting fibrous cap degradation and plaque disruption. 1, [3] [4] [5] [6] Conversely, interventions that regress atherosclerosis and stabilize plaques have been associated with reduced inflammation and a diminution in plaque macrophage content. 7, 8 There is increasing evidence that the lesion macrophage population is not static, but is involved in ongoing influx and excursion. 9 Despite the critical role played by macrophages, noninvasive magnetic resonance imaging (MRI) techniques for their accurate quantification are still imperfect. 10 Monocyte recruitment to the vascular wall is promoted by upregulation of endothelial adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1; CD106) and P-selectin (CD62P) at atherosclerosis-prone sites. [11] [12] [13] Initial monocyte-endothelial interactions are mediated by P-selectin, which stimulates monocyte rolling along the activated endothelium 13 whereas firm adhesion of monocytes depends on the engagement of integrin 41 (also termed very late antigen-4 [VLA-4]) with endothelial VCAM-1, preceding their transmigration to the nascent lesion. 14, 15 Appreciation of these mechanisms and their relevance to atherogenesis lay a foundation for the design of molecular imaging probes that can determine, noninvasively, in vivo, the propensity of regional arterial endothelial activation to attract monocytes. [16] [17] [18] To image vascular endothelial cell activation with MRI, we previously developed prototypic 4.5-μm diameter microparticles of iron oxide (MPIO) conjugated to antibodies against both VCAM-1 and P-selectin. 19 Although this approach proved promising in feasibility experiments demonstrated by ex vivo MRI of explanted mouse aortas (with advanced atherosclerosis), retention of MPIO was insufficient at acceptable iron doses for reliable in vivo molecular MRI. To overcome this limitation, we have developed a second generation of smaller (1.0 μm) MPIO that have higher surface area to volume ratio for polyvalent ligand conjugation and which, we hypothesized, would be less buoyant under conditions of flow and high shear stress. These micron size-range particles should be distinguished from the targeted 20 or untargeted 21, 22 nanoscale particles that have more commonly been used for atherosclerosis imaging. Compared with nanoscale particles, MPIO offer distinct advantages: (1) the payload of iron and, therefore, sensitivity is high 23,24 ; (2) the clearance of MPIO from circulation is very rapid so background blood phase contrast is minimal 25 ; (3) the obligate intravascular MPIO are much more tractable for endothelial molecular imaging than nanoparticles, which are susceptible to passive accumulation 26, 27 ; and (4) they are readily functionalized allowing conjugation of 1 or more high valency targeting ligands. [28] [29] [30] Accordingly, we have developed a leukocyte-mimetic contrast agent, based on size and surface ligands, which targets both VCAM-1 and P-selectin. We test the extent to which dual-ligand leukocyte-mimetic MPIO home to activated endothelium and reflect inflammatory cell content in vivo across a range of atherosclerotic lesion complexities in apolipoprotein E deficient (apoE −/− ) mice. We further determine cellular binding patterns of dual-ligand MPIO in regions of the aorta that are susceptible to atherosclerotic lesion development. In doing so, we have sought to use the leukocytemimetic properties of MPIO to map vascular inflammation in atherosclerosis.
Methods
A detailed online-only Data Supplement methods section is available online.
Preparation of MPiO
Rat antimouse monoclonal VCAM-1 (clone M/K2; Cambridge Bioscience Ltd, Cambridge, United Kingdom) and P-selectin antibodies (CD62P clone RB40.34; BD Biosciences, Oxford, United Kingdom) were covalently conjugated to the surface of tosyl-activated MPIO (1 μm diameter; Invitrogen, Paisley, United Kingdom) in a 50:50 ratio to produce dual-ligand MPIO targeted to P-selectin and VCAM-1 (PV-MPIO), as previously described. 26, 31 Isotype control rat IgG-1 antibody (clone Lo-DNP-1; Abd Serotec, Oxford, United Kingdom) conjugated MPIO (IgG-MPIO) were also prepared. For fluorescence imaging using en face immunofluorescence and flow cytometry, near-infrared fluorescently labeled dual-ligand MPIO were developed. P-selectin and VCAM-1 monoclonal antibodies (50:50 mix) were combined with a near-infrared Alexa Fluor 750 dye for 60 minutes at room temperature according to the small animal in vivo imaging (SAIVI) Alexa Fluor 750 antibody labeling kit (Invitrogen), which is azide-free and thus suitable for in vivo applications. Approximately 2 Alexa Fluor 750 molecules were coupled to each antibody molecule, according to the manufacturer's protocol. The SAIVI 750 labeled P-selectin and VCAM-1 antibody mix was purified by gel column filtration, and then conjugated to the surface of tosyl MPIO, as above. The SAIVI 750 dual-ligand MPIO were stored in the dark at 4°C. For in vitro flow chamber experiments, MPIO conjugated to mouse antihuman P-selectin and VCAM-1 antibodies or their counterligands, P-selectin glycoprotein ligand-1 (PSGL-1) or VLA-4  4  1 were developed (online-only Data Supplement methods).
Mouse Atherosclerosis
Female apoE −/− knockout mice on a C57BL/6 background were weaned at 3 weeks and fed a standard rodent chow diet ad libitum. Mice underwent MRI after 8, 14, 20, and 30 weeks on chow diet to determine the ability of dual-ligand MPIO to track endothelial adhesion molecule expression from early foam cell formation to more advanced atherosclerotic lesions. Animal procedures were performed in accordance with UK Home Office Animals (Scientific Procedures) Act 1986.
in Vivo Mri
Mice underwent in vivo MRI of the aortic root using a 9.4-Tesla horizontal magnet interfaced to a VNMRS DirectDrive MR System (Varian Inc, Palo Alto, CA). Animals were anesthetized with 4% isofluorane in O 2 gas mixture and maintained with 1.5% to 1.8% isofluorane in 100% O 2 (3 L/min) delivered through a nose cone and positioned in a cradle in a 33-mm birdcage coil (Rapid Biomedical, Rimpar, Germany). Cardiac and respiratory signals were continuously monitored using an in-house developed ECG and respiratory gating device. 32 The aortic root was identified in a coronal section on a localizing sequence. To determine the MPIO contrast effects, T 2 *-weighted images were acquired in end-diastole using a doublegated, flow-compensated, segmented 3-dimensional gradient echo sequence (echo time/repetition time2.4/4.0 milliseconds, repetition time per segment 120-150 milliseconds depending on heart rate, 2 k-space lines per cardiac cycle; matrix size 25625648; number of signal averages 1, slice thickness 8 mm, field of view 303012 mm; flip angle 15°; reconstructed resolution 5959125 μm 3 ). After precontrast imaging, the mice were administered either dual-ligand PV-MPIO (n56-7 per group) or control IgG-MPIO (n52-3 per group; 3.3 mg Fe/kg body weight) via tail vein injection. Postcontrast images were acquired at <30 minutes and <60 minutes after MPIO injection. Mice were terminally anesthetized with isofluorane and perfusion fixed with 4% paraformaldehyde. Histopathologic examination of aortic roots was performed (online-only Data Supplement methods).
Mri Analysis
Aortic root low signal intensity areas were measured by drawing an area of interest around the outer wall of the aortic root using Image-Pro Plus version 6.1. The threshold of low signal, corresponding to MPIO binding, was defined to be 3 SDs below the mean signal intensity of the precontrast root on signal intensity histograms. This threshold was applied to sequential MR slices through the aortic root, before and after MPIO contrast, to determine the mean area of MPIO low signal contrast. Pseudocolored maps of bound MPIO were generated using the same gray scale thresholds, to visualize the distribution and magnitude of MPIO signal intensities in the aortic root wall, using a pseudocolor range from 0 to 255 colors. The contrast-to-noise ratios (CNR) of identified MPIO-positive lesion areas were compared with the CNR of equivalent areas on the precontrast images as CNR5blood pool signal−lesion signal/SD of the noise as previously described. 33 
Flow cytometry
To assess the cellular distribution of dual-ligand MPIO binding, flow cytometry experiments were performed on cell suspensions from disaggregated whole aortas (online-only Data Supplement methods). Whole blood from apoE −/− mice was also assessed to establish whether there was binding of dual-ligand MPIO to circulating platelets. Apo E −/− mice (n53), 20 weeks on chow diet, were injected intravenously with near-infrared SAIVI 750 PV-MPIO (3.3 mg/kg). After 60 minutes of circulation, mice were terminally anesthetized and perfused with ice-cold PBS. Aortas from apo E −/− mice (n53) without MPIO injection served as controls.
en Face immunofluorescence
ApoE −/− mice, 20 weeks on chow diet, were injected with near-infrared SAIVI 750 labeled PV-MPIO (3.3 mg/kg). After 60 minutes, mice were terminally anesthetized, and aortas perfused in situ with PBS and then 4% paraformaldehyde via the left ventricle. Aortas were further fixed in 4% paraformaldehyde for 30 minutes. Mouse aortas were examined using en face immunofluorescence (onlineonly Data Supplement methods) to assess the binding patterns of dual-ligand MPIO binding in regions of the proximal and descending aorta with high and low probability for atherosclerotic lesion development. 34, 35 statistical Analysis
Results are expressed as meanSD. GraphPad Prism 5 (GraphPad Software, Inc, San Diego, CA) was used for statistical analysis.
For imaging experiments with multiple groups, differences were evaluated using 2-way ANOVA. Unpaired 2-tailed Student t tests were applied to determine differences between 2 groups and paired 2-tailed Student t tests to compare differences in MRI data within a group before and after MPIO administration. Spearman rank nonparametric correlations were performed to correlate MRI and histological quantification of aortic root dual-ligand MPIO binding and the relationship between aortic root lesion macrophage content and dual-ligand MPIO binding. The significance level in all tests was P0.05.
results

Antibody-conjugated MPiO show High Binding Affinity to stimulated endothelial cells in Vitro
To test surface orientation of the cognate ligands VLA-4 and PSGL-1 conjugated to MPIO, the particles were incubated with human recombinant VCAM-1-fragment crystallizable or human recombinant P-selectin-fragment crystallizable chimeras. Figure 1A shows green fluorescent MPIO confirming binding of VLA-4-MPIO to recombinant VCAM-1 and PSGL-1-MPIO to recombinant P-selectin. There was no binding of PSGL-1-MPIO to recombinant VCAM-1fragment crystallizable but VLA-4-MPIO showed some cross reactivity to recombinant P-selectin-fragment crystallizable. In cellular binding experiments, quantification of MPIO adherent to stimulated human umbilical vein endothelial cells after 5 minutes of flow showed that antibody-conjugated MPIO were retained significantly more than either VLA-4-MPIO (18-fold; P0.0001) or PSGL-1-MPIO (185-fold; P0.01; Figure 1C ). Antibodyconjugated MPIO were therefore used for in vivo experiments in mice. To determine whether dual-ligand MPIO can detect endothelial activation in vivo, MRI was performed at 8, 14, 20, and 30 weeks during atherosclerotic lesion development. Representative MRI of aortic root atherosclerotic lesions preand postinjection of either dual-ligand MPIO or negative control IgG-MPIO are shown in Figure I in the online-only Data Supplement. MRI showed highly conspicuous areas of low signal after dual-ligand MPIO injection, with minimal MR signal effects observed in precontrast images and in aortic root images of mice injected with control IgG-MPIO. Sequential MRI through the root showed strong low signal areas 30 minutes post-MPIO injection, which persisted at similar levels at 60 minutes (Figure 2A ). Pseudocolor maps illustrated the localization and magnitude of the T 2 * signal intensity enhancement in the aortic root wall ( Figure 2B ). Contrast effects were confined to regions of the root affected by atherosclerosis and not to lesion-free areas, as confirmed by histology ( Figure 2C ). The CNR of MPIO-positive lesion areas and adjacent blood pool increased by 87% (P0.05), 100% (P0.01), and 96% (P0.01) at 14, 20, and 30 weeks, respectively, compared with equivalent precontrast aortic lesion areas. No difference in lesion CNR was observed between time-points.
Semiquantitative analysis of the area of PV-MPIO contrast effects in the aortic roots showed minimal detectable MR contrast effects at 8 weeks, with a 3.9-fold increase in the area of low MR contrast effects at 14 weeks (P0.05), and a further 1.8-fold increase by 20 weeks (P0.05). However, at 30 weeks, there was a 1.8-fold reduction in MR contrast effects compared with 20 weeks (P0.01; Figure 3A) .
To test whether MR contrast effects reflected MPIO retention, the number of bound PV-MPIO was quantified by histology ( Figure 3B ). Significant increases in the number of PV-MPIO binding were observed at 14 and 20 weeks, with a reduction at 30 weeks, reflecting the MR contrast effects. The number of bound PV-MPIO quantified by histology correlated with MR signal intensity areas corresponding to aortic root PV-MPIO binding (P0.001; Figure 3C ). Irrespective of age, dual-ligand MPIO localized only to endothelium overlying atherosclerotic lesions, with no MPIO seen within lesions or bound to lesion-free endothelium. Immunohistochemistry for VCAM-1 confirmed endothelial activation on atherosclerotic lesions ( Figure 3D ).
dual-ligand MPiO Binding Tracks Quantitatively With lesion Macrophage content
To investigate whether dual-ligand MPIO accumulation tracked with macrophage content within the lesion over time, aortic root sections were immunostained for Gal-3 ( Figure 4A ). Lesion macrophage area increased between 8 and 14 weeks, with a further increase by 20 weeks. However, between 20 and 30 weeks, there was a significant reduction in total macrophage area, which reflected the pattern of dual-ligand MPIO binding to the overlying endothelium ( Figure 3B ). Total lesion size also increased up to 20 weeks, but between 20 and 30 weeks, plaque size remained constant ( Figure 4B ). Lesion macrophage area correlated with dual-ligand MPIO binding to the aortic root assessed by in vivo MRI (R50.53; P0.01; Figure 4C ).
dual-ligand MPiO Bind to Activated endothelial cells at Atherosclerosis-susceptible sites
To test the cellular specificity of MPIO binding in this context, we developed dual-ligand MPIO, fluorescently labeled with a near-infrared SAIVI Alexa Fluor 750 fluorophore. Flow cytometry was performed on cellular suspensions from digested aortas and whole blood of mice 60 minutes after intravenous injection of near-infrared SAIVI 750 PV-MPIO. Binding was predominantly to VCAM-1-positive (CD31 + CD11b − ) aortic endothelial cells, with a minority bound to nonactivated VCAM-1-negative endothelial cells (P0.01). There was no association of MPIO with VCAM-1 + CD31 − cells, and only minimal MPIO uptake observed for macrophages (CD11b + F4/80 + ; Figure 5 ). Analyses of whole blood found that 22% of cells were CD41 + CD11b − platelets, of which 1% was CD41 + CD11b − CD62P + . No MPIO binding to CD41 + CD11b − or to CD41 + CD11b − CD62P + circulating platelets was detected ( Figure II in the online-only Data Supplement).
Predisposition to atherosclerosis is asymmetrical in the proximal aorta with VCAM-1 upregulation in the atherosclerosis-prone lesser curvature and is relatively sparing in the greater curvature of the arch and descending tubular aorta. We next investigated the spatial localization of near-infrared SAIVI 750 dual-ligand MPIO binding in the aorta using en face immunofluorescence microscopy. Endothelial cells in the atherosclerosis-susceptible (high probability region) inner curvature of the aortic arch displayed irregular cuboidal shapes, which did not align longitudinally and showed upregulation of VCAM-1 ( Figure 6A ). PV-MPIO were selectively retained by the endothelial in this area compared with the atherosclerosis-resistant outer curvature (low probability region) of the aortic arch and descending aorta, which displayed endothelial cells of normal shape and alignment, with minimal levels of VCAM-1 expression ( Figure 6B ).
discussion
Quantitative assessment of local vascular inflammation is a key goal in the diagnosis and characterization of vascular disease and is likely to become more important because drugs directly targeting inflammatory pathways are developed for the treatment of high-risk patients with atherosclerosis. 16, 18, 36 The vascular endothelium is the principal regulatory interface that governs the recruitment of mononuclear cells to sites of injury and inflammation, through the upregulation of adhesion molecules, and is therefore an important target for this purpose. 13, 37 Here, we demonstrate specific in vivo molecular imaging of endothelial cell activation during atherosclerotic lesion development in apoE −/− mice using leukocyte-mimetic MPIO, targeting both VCAM-1 and P-selectin. These particles rapidly achieve steady state accumulation at target and provide exceptionally conspicuous, objectively quantifiable contrast effects. The MR contrast effects generated by dualligand MPIO binding also tracked quantitatively with lesion macrophage content across a range of lesion complexities. However, we show through both microscopy and flow cytometry that MPIO binding is confined to activated endothelial cells, and they are not bound to, or taken up by, macrophages within plaque. Using en face techniques to evaluate anatomically distinct areas of aorta, we further demonstrate selective binding of PV-MPIO in atherosclerosis-prone segments of the aortic arch that were associated with VCAM-1 upregulation and loss of normal endothelial cell architecture.
Adhesion molecule upregulation was identified during early foam cell lesion, at 14 weeks on chow diet, with a further increase detected at 20 weeks, in fibrofatty lesions. However, at 30 weeks, in vivo MRI quantification detected a significant, apparently paradoxical reduction in adhesion molecule expression. However, histological examination showed that PV-MPIO accumulation faithfully reflected actual changes in macrophage content. This is consistent with regulation of monocyte influx at the level of the vascular endothelium, with overall lesion macrophage content reflecting the net effects of recruitment versus egress, apoptosis, and necrosis. 9 In addition, the distribution of PV-MPIO was spatially related to the areas of the root showing foam cell formation, while nonlesional areas did not retain MPIO. This agrees with reports that VCAM-1 is most strongly upregulated in vascular endothelium overlying plaque. 38 Molecular imaging approaches benefit from rapid accumulation and attainment of steady state at target, with clearance of unbound (blood phase) contrast. Serial imaging revealed that PV-MPIO accumulated by 30 minutes on activated vascular endothelium and was maintained at 60 minutes, thus providing a practical imaging time frame. In an alternative strategy, peptides generated by phage display have been selected to bind specifically to activated endothelium and conjugated to nanoparticles. 20 After binding to VCAM-1, the nanoparticles are internalized by endothelial cells and macrophages over 24 to 48 hours, allowing progressive concentration sufficient for noninvasive imaging applications. Our work builds on these previous approaches to imaging activated endothelium by providing exceptionally conspicuous contrast within 30 minutes (rather that 24-48 hours), without the need for intracellular accumulation and thereby maintaining specificity for the original molecular targets. Furthermore, flow cytometry of single-cell suspensions from digested aortas showed that near-infrared SAIVI 750 dual-ligand MPIO bound specifically to activated endothelial cells and were not taken up by macrophages or other cell types.
In common with earlier studies, 19, 33 we imaged the aortic root in its short axis, because atherosclerotic lesions develop here early in apoE −/− mice and progress in a semipredictable fashion. 39, 40 Second, the aortic valve position in relation to the chambers of the heart provides an excellent fiducial reference to align both the imaging plane and circumferential orientation. As shown in Figure 3 , an eccentric lesion identified with in vivo contrast MRI is readily confirmed in tissue section.
Endothelial activation also occurs early in regions of endothelium prone to the development of atherosclerosis. Regions of low shear stress are associated with loss of the normal endothelial cell shape, disorganized endothelial cells that do not align in the direction of blood flow, and increased expression of cell adhesion molecules. Using en face immunofluorescence, we show that the atherosclerosis-prone region of the aortic arch retains dual-ligand MPIO in association with VCAM-1 upregulation whereas the relatively atheroresistant portions of aorta maintained normal endothelial cell morphology; aligned in the direction of flow, low level cell adhesion molecule expression, and absent MPIO binding. Previously, microbubbles targeted to either P-selectin or VCAM-1 have been applied for molecular imaging of early atherosclerosis progression, which showed preferential binding to lesionprone areas in the aortic arch, with similar increases in endothelial P-selectin and VCAM-1 expression in atherosclerotic lesions with age. 41 In seeking the optimal leukocyte-mimetic MPIO, we compared the interactions of the cognate ligands VLA-4 and PSGL-1 with the antibody-targeting approach. After confirming that these natural ligands were conjugated and orientated on MPIO, we found that their binding to activated endothelial cells under low shear stress conditions in vitro had neither the specificity nor affinity of antibodies. We had reasoned that the cognate ligands may show greater affinity and would be less immunogenic in any future translational application. However, even on leukocytes the mere expression of ligands is not sufficient to attain binding, which is dependent on conformational change/clustering on the cell membrane, orchestrated by the cytoskeleton. 42 We therefore pursued an antibody-based approach, using our earlier observations in a flow chamber model 43 and in vivo 19 that a dual targeting strategy directed at both cell adhesion molecules and selectins is more effective than either alone.
The MPIO that we have used are not suitable for human use due to their nonbiodegradable polyurethane coat. However, surface-functionalized biodegradable, dextran-coated MPIO have recently been developed that are actively taken up by macrophages in the liver and spleen, and rapidly dispersed through the specific action of macrophage cathepsins. 44, 45 Combined with humanized antibodies, to minimize immunogenicity, these particles are potentially suitable for human testing. The dose of MPIO administered in our study was 3.3 mg Fe/kg body weight, which is similar to that used clinically for nontargeted iron contrast agents in oncological imaging (2.6 mg/kg) 46 and significantly lower than some ultrasmall particles of iron oxide doses used experimentally for imaging larger animal models such as rabbits (11-56 mg/kg). 21, 47 Atherosclerotic plaque macrophage content and activity are important determinants of plaque instability, and the ability to image these may also be important in predicting risk. 48 Monocytes have been shown to be actively recruited in a progressive manner that is proportional to the extent of atherosclerotic disease. 49 Treatments that reduce lesion macrophage content have also been shown to reduce VCAM-1 expression. 50, 51 The correlation between endothelial-bound dual-ligand MPIO and lesion macrophage content, and thus putatively that dual-ligand MPIO behave as a monocytemimetic, may provide a novel imaging probe to assess the localization and extent of inflammatory atherosclerotic disease. Considerable effort has been directed toward the use of 2-[ 18 F]fluoro-2-deoxy-d-glucose for positron emission tomography assessment of atherosclerotic plaque inflammation, with success in identifying acute lesions 36 and in monitoring response to therapy. 36, 52 However, while [ 18 F] fluoro-2-deoxy-d-glucose appears to be preferentially taken up by inflammatory macrophages, a recent in vitro study suggests that this technique may be sensitive to hypoxia in plaque macrophages rather than measuring inflammation per se. 53 MPIO, attributable to their relatively large size, do not penetrate the vessel wall, and therefore remain highly specific for targeting endothelial molecular markers. This is unlike untargeted ultrasmall superparamagnetic iron oxide, which are subject to vascular egress and passive accumulation within atherosclerotic lesions or uptake by macrophages. 21, 22 The rapid binding kinetics of dual-ligand MPIO, coupled with the immediate 19 accessibility of endothelial cells (without the need to permeate the plaque), distinguish targeted MPIO as a powerful molecular imaging platform. The expression of endothelial cell adhesion molecules is not specific to any given stage or size of lesion. Therefore, if used in clinical practice, it would be anticipated that molecular imaging of endothelial inflammation would be combined in an integrated examination of vessel characterization with soft tissue arterial wall imaging and MR angiography.
conclusions
We have developed a leukocyte-mimetic contrast agent, for in vivo molecular MRI, that rapidly homes to activated vascular endothelium during atherosclerotic lesion development. Although confined to the intravascular compartment and bound to endothelium, in the context of atherosclerosis in the aortic root, the accumulation of MPIO contrast agent quantitatively tracked with atherosclerotic lesion macrophage content. This approach provides new and significant benefits:
(1) exceptionally rapid steady state accumulation; (2) unusually conspicuous MR contrast effects that can be objectively quantified using semiautomated techniques; and (3) faithful reflection of endothelial activation associated with leukocyte accumulation. As degradable biocompatible particles become available, this potent platform may find utility in both imaging and, potentially, drug delivery.
